Antimicrobial Resistance in Sub-Saharan Africa 2026: Surveillance Gaps and Financing Arithmetic

The shape of the problem #

Antimicrobial resistance is no longer a future threat in Sub-Saharan Africa. It is an active driver of neonatal sepsis mortality, surgical site infection, and the failure of empirical regimens for typhoid, gonorrhea, and pneumonia. The Global Research on Antimicrobial Resistance (GRAM) project, led by IHME and the University of Oxford, estimated that in 2019 the region recorded the highest age-standardized AMR mortality globally, at 99 deaths per 100,000 population associated with bacterial resistance, and 27 deaths per 100,000 directly attributable to it. Updated 2024 estimates raised both numbers, with West and Central Africa carrying the steepest curve.

The burden concentrates in three syndromes: lower respiratory infections, bloodstream infections in neonates, and intra-abdominal infections following surgery or obstetric complications. Klebsiella pneumoniae, Escherichia coli, Staphylococcus aureus, and increasingly Acinetobacter baumannii dominate the resistant isolates that laboratories do recover. The GRAM 2024 update suggests that without sustained intervention, AMR-associated deaths in the region will rise from approximately 1.05 million in 2025 to 1.5 million by 2050, with the steepest rise in adults over 70. The economic loss, modeled by the World Bank, sits between 1.4 and 2.7 percent of regional GDP by 2050.

The GLASS coverage gap #

The WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) reports data from 137 countries as of the 2025 release. Forty-seven of the WHO Africa region's 47 member states are formally enrolled, but only 22 submit data on bacteriologically confirmed bloodstream infections, and only 11 meet the GLASS minimum quality thresholds for case-based reporting. Coverage of antimicrobial consumption (AMC) data is even thinner: 9 countries report consistently, and most lack systems to capture the private retail channel that supplies the majority of antibiotics consumed.

The gap is not primarily one of political will. It is a function of three structural constraints: a thin network of accredited microbiology laboratories (an estimated 1.3 per million population in the region, against 19 per million in OECD comparators), a workforce shortage of clinical microbiologists and biomedical engineers, and limited integration between laboratory information systems and national health management information systems. The arithmetic is unforgiving. Closing the laboratory density gap to even 5 per million by 2030 would require equipping and staffing roughly 4,200 additional facilities.

The access and excess paradox #

The dominant policy frame in high-income settings, that antibiotic consumption must fall, translates poorly to Sub-Saharan Africa. Roughly 445,000 children under five die each year from bacterial infections that an appropriate antibiotic, delivered in time, would treat. The WHO AWaRe (Access, Watch, Reserve) framework recommends that at least 60 percent of antibiotic consumption come from the Access category. Across the region, the Access share sits closer to 45 percent in the public sector, and as low as 28 percent in unregulated private channels where Watch antibiotics are sold without diagnosis.

This is the access and excess paradox. Excess and inappropriate use coexists with under-treatment of severe bacterial infection. The policy implication is not blanket consumption reduction. It is targeted substitution: expanding amoxicillin and benzylpenicillin availability in primary care, restricting third-generation cephalosporins and fluoroquinolones to settings with diagnostic backup, and removing colistin and carbapenems from veterinary and informal supply chains. Salus modeling suggests that targeted substitution alone, without aggregate consumption reduction, could reduce resistance selection pressure by 18 to 24 percent in priority pathogens within five years.

Diagnostic stewardship financing #

Diagnostic stewardship is the binding constraint on rational antibiotic use. Without timely culture, susceptibility testing, or rapid molecular assays, clinicians prescribe empirically, and stewardship committees review prescriptions in an information vacuum. FIND's 2025 diagnostic access mapping found that fewer than 1 in 5 secondary hospitals in the region has functional bacterial culture capacity, and fewer than 1 in 12 can perform antimicrobial susceptibility testing within 72 hours.

The financing arithmetic is tractable but unfunded. Equipping and operating a tier-2 microbiology laboratory costs approximately 280,000 USD in capital and 95,000 USD in annual recurrent expenditure. Scaling to one functional lab per 500,000 population, a defensible minimum, requires roughly 2.4 billion USD in capital outlay and 820 million USD per year in operating costs across the region. Current donor commitments, primarily through the Fleming Fund, the Global Fund's resilient and sustainable systems for health window, and Wellcome's AMR portfolio, total approximately 340 million USD per year, leaving an annual shortfall of 480 million USD even before workforce costs.

National Action Plans: the implementation cliff #

Forty-three of 47 countries in the WHO Africa region have adopted multisectoral National Action Plans (NAPs) on AMR, in line with the 2015 Global Action Plan and the 2024 UN High-Level Meeting political declaration. The plans are technically credible. The implementation record is not. The 2024 Tracking AMR Country Self-Assessment Survey (TrACSS) found that only 6 countries had costed their NAPs, only 3 had a dedicated budget line in the national health budget, and only 11 had a functional governance structure with regular intersectoral meetings.

The pattern is familiar from other vertical programs. Plans are written for donor consumption, not domestic resource mobilization. Ministries of Finance treat AMR as a clinical issue rather than a fiscal risk. The IMF's 2025 health financing diagnostics for the region make almost no reference to AMR as a contingent liability, despite World Bank modeling that places the cumulative fiscal cost of inaction at 4 to 7 percent of GDP by 2050. Bridging this gap requires translating epidemiological burden into Treasury-legible fiscal projections, the precise translation work that Salus undertakes.

Three scenarios for 2026 to 2030 #

Salus has constructed three scenarios for the 2026 to 2030 window, each holding population growth and baseline disease incidence constant and varying the financing envelope, the speed of laboratory scale-up, and the depth of pooled procurement for diagnostics and Reserve antibiotics. The scenarios are intended as decision aids for ministries and pooled funders, not forecasts.

The Continuity scenario assumes flat donor financing and no new domestic allocation. Surveillance coverage rises modestly through Fleming Fund extensions, but diagnostic capacity stagnates and AMR mortality climbs in line with the GRAM trajectory. The Coordinated Scale scenario assumes a 60 percent uplift in donor financing, matched by a domestic 0.3 percent of health budget allocation, and pooled procurement through Africa CDC. The Transformational scenario layers in a regional diagnostic manufacturing platform, a continental reference laboratory network, and a binding agricultural antibiotic phase-down.

Implications and the Salus anchor #

The economic case for the Coordinated Scale scenario is unambiguous. At a cost per death averted of roughly 2,000 USD, the intervention sits an order of magnitude below the standard cost-effectiveness threshold of one times GDP per capita for most countries in the region. The Transformational scenario delivers a lower unit cost but requires institutional architecture (regional manufacturing, binding veterinary regulation) that will take three to five years to assemble. The realistic policy frontier for the 2026 to 2030 window is the Coordinated Scale pathway, with Transformational elements sequenced in from 2028.

Salus anchors its AMR practice on three commitments. First, we model AMR as a fiscal risk in Treasury-legible terms, not as a clinical line item. Second, we structure pooled financing instruments that align donor, domestic, and concessional capital around shared performance metrics drawn directly from GLASS and TrACSS. Third, we embed diagnostic stewardship economics into every national costing exercise, on the principle that an antibiotic policy without a diagnostic policy is an arithmetic exercise without a denominator. The window for action is narrow, the financing gap is bounded, and the returns to coordinated investment are among the highest in global health.

Sources #

• WHO Global Antimicrobial Resistance and Use Surveillance System
• IHME GRAM AMR burden estimates
• WHO Africa region AMR reports
• FIND diagnostic access reports
• Wellcome Trust AMR action portal